^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Chong Kun Dang, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    5d
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=187, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    9d
    GLIA-MAC: Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy (clinicaltrials.gov)
    P=N/A, N=60, Completed, Federico II University
    New trial
    |
    Eylea (aflibercept intravitreal)
    12d
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=172, Not yet recruiting, Alvotech Swiss AG | N=102 --> 172
    Enrollment change
    |
    Eylea (aflibercept intravitreal)
    14d
    A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Exegenesis Bio | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    14d
    EYP-1901-303: COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (2025-523937-25-00)
    P2/3, N=37, Not yet recruiting, Eyepoint Pharmaceuticals Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    21d
    EYP-1901-304: CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (2025-523938-10-00)
    P2/3, N=50, Not yet recruiting, Eyepoint Pharmaceuticals Inc.
    New P2/3 trial
    |
    Eylea (aflibercept intravitreal)
    22d
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=333, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    23d
    Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Sam Chun Dang Pharm. Co. Ltd.
    New P2 trial
    |
    Eylea (aflibercept intravitreal)
    28d
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=480, Active, not recruiting, 4D Molecular Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    29d
    A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=356, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    30d
    ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=256, Not yet recruiting, Alvotech Swiss AG
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (clinicaltrials.gov)
    P3, N=284, Recruiting, Adverum Biotechnologies, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)